Phase 3 PIVOT-006 topline data are expected in the near term; BLA completion targeted for Q4 2026 for HR BCG-unresponsive NMIBC with CIS.
Q2 FY26 financial results and spending
CG Oncology posted a net loss of USD 79.1 million, or USD 0.90 per share, for Q2 2026.
R&D expense climbed to USD 54.7 million from USD 31.3 million a year earlier, due to higher clinical trial and CMC costs and higher headcount.
G&A expense rose to USD 29.0 million from USD 17.4 million, driven by higher personnel costs from increased headcount.
Cash, cash equivalents and marketable securities totaled USD 1.0 billion at June 30, down from USD 1.1 billion at March 31; funding runway through 2029.
CGON•
